2017-03-21,NeuroDerm To Host Fourth Quarter And 2016 Fiscal Year Financial Results Conference Call On March 30, 2017
2017-03-02,First Week of NDRM August 18th Options Trading
2017-03-01,NeuroDerm Achieves Primary Endpoint In ND0612H Phase II Trial For Advanced Parkinson's Disease; Seeks Broader EU Label Based On INDiGO Trial Following EMA Meeting
2017-02-27,NeuroDerm CEO To Present At Upcoming Investor Conferences
2017-01-26,NeuroDerm Announces Extraordinary General Meeting Of Shareholders
2017-01-03,NeuroDerm CEO To Present At The 35th Annual J.P. Morgan Healthcare Conference On January 12, 2017
2016-12-23,Neuroderm Has a Promising Pipeline
2016-12-22,NeuroDerm Announces Closing Of Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
2016-12-22,NeuroDerm Announces Completion Of Patient Enrollment And Treatment In A Phase II Trial Of ND0612H For Advanced Parkinson's Disease
2016-12-12,NeuroDerm Announces Closing Of A Follow-On Offering Of Ordinary Shares
2016-12-07,NeuroDerm Announces Pricing Of A Follow-On Offering Of Ordinary Shares
2016-12-06,NeuroDerm Announces Launch Of A Follow-On Offering Of Ordinary Shares
2016-12-05,NeuroDerm To Replace Two Phase 3 Clinical Trials With Small Pharmacokinetic Trials Following FDA Meeting On ND0612 Regulatory Development
2016-12-02,NeuroDerm Announces Top-Line Results Of Pilot PK Trial Comparing ND0701 With Commercial Apomorphine
2016-11-10,NeuroDerm Announces Third Quarter 2016 Financial Results
2016-11-03,NeuroDerm CEO To Present At Upcoming Investor Conferences
2016-11-01,NeuroDerm To Host Third Quarter 2016 Financial Results Conference Call On November 10, 2016
2016-09-29,NeuroDerm Provides Updates On ND0612 Long-Term Safety Trial And Submission Of Marketing Applications
2016-09-22,NeuroDerm's ND0612 Mini-Pump Delivery System Successfully Used By Parkinson's Disease Patients In Home Setting
2016-09-19,NeuroDerm To Present ND0612 Data At 4th World Parkinson Congress Demonstrating Ease Of Use Of Mini-Pump Delivery System
2016-08-25,NeuroDerm Announces Second Quarter 2016 Financial Results And Provides Corporate Update
2016-08-25,NeuroDerm Initiates Patient Enrollment In A Phase III Trial Of ND0612L For The Treatment Of Parkinson's Disease
2016-08-11,NeuroDerm To Host Second Quarter 2016 Financial Results Conference Call On August 25, 2016
2016-07-27,NeuroDerm Announces Issuance Of A New U.S. Patent For Aqueous Apomorphine Covering Concentrated Subcutaneously Delivered Pharmaceutical Compositions
2016-07-26,NeuroDerm Announces Start Of Bioequivalence Trial In Healthy Volunteers Of ND0701, A New Continuous Subcutaneously Delivered Apomorphine Product Candidate For The Treatment Of Advanced Parkinson's Disease
2016-07-06,NeuroDerm Announces Additions To Management Team
2016-07-05,NeuroDerm To Present At The Cantor Fitzgerald Healthcare Conference On July 13
2016-06-30,NeuroDerm Announces Start Of U.S. Patient Enrollment In Trial 006, A Phase II Trial Of ND0612H For Advanced Parkinson's Disease
2016-06-28,NeuroDerm Announces ND0612H Achieves Comparable Pharmacokinetics To DUODOPA® In Head-To-Head Pilot PK Comparison Trial
2016-06-24,NeuroDerm Added To Russell Global Index
2016-06-23,NeuroDerm Presents Three Posters At The 20th International Congress Of Parkinson's Disease And Movement Disorders
2016-06-16,NeuroDerm To Present Design Of The First Clinical Efficacy Study Of ND0612H And Other Clinical Data At The 20th International Congress Of Parkinson's Disease And Movement Disorders
2016-05-31,NeuroDerm CEO To Present At Jefferies 2016 Healthcare Conference On June 7
2016-05-26,NeuroDerm Announces First Quarter 2016 Financial Results
2016-05-17,NeuroDerm To Host First Quarter 2016 Financial Results Conference Call On May 26, 2016
2016-05-09,NeuroDerm Announces Patient Enrollment In Long-Term Safety Trial Of ND0612 For Parkinson's Disease
2016-05-05,NeuroDerm Announces 2016 Annual General Meeting Of Shareholders
2016-04-22,NeuroDerm Announces Removal Of FDA Import Alert Of Infusion Pumps Used In ND0612 Clinical Trials
2016-04-05,NeuroDerm Parkinson's Disease Clinical Data Selected For Two Oral Presentations At The American Academy Of Neurology 68th Annual Meeting
2016-03-31,NeuroDerm Announces Fourth Quarter And Full Year 2015 Financial Results And Provides A Corporate Update
2016-03-22,NeuroDerm To Host Fourth Quarter And 2015 Fiscal Year Financial Results Conference Call On March 31, 2016
2016-03-02,NeuroDerm To Present At Upcoming Investor Conferences
2016-02-08,NeuroDerm Enters Oversold Territory (NDRM)
2016-01-11,NeuroDerm is Now Oversold (NDRM)
2016-01-04,NeuroDerm CEO To Present At The 34th Annual J.P. Morgan  Healthcare Conference On January 14, 2016
2015-12-30,NeuroDerm Announces Start Of Patient Enrollment In Phase II Trial Of ND0612H For Advanced Parkinson's Disease
2015-12-18,NeuroDerm Added To The Nasdaq Biotechnology Index
2015-11-12,NeuroDerm CEO To Present At Upcoming Investor Conferences
2015-11-11,NeuroDerm Announces Third Quarter 2015 Financial Results
2015-11-11,NeuroDerm Announces Streamlined U.S. Development Plan Following FDA Feedback On ND0612H And ND0612L For The Treatment Of Parkinson's Disease
2015-11-04,NeuroDerm To Host Third Quarter 2015 Financial Results Conference Call On November 11, 2015
2015-09-24,NeuroDerm Announces 2015 Annual General Meeting Of Shareholders
2015-08-06,NeuroDerm Announces Second Quarter 2015 Financial Results And Provides Corporate Update
2015-07-30,NeuroDerm To Host Second Quarter 2015 Financial Results Conference Call On August 6, 2015
2015-07-21,NeuroDerm Ltd. Announces Closing Of Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-07-15,NeuroDerm Ltd. Announces Pricing Of Public Offering
2015-07-02,NeuroDerm Ltd. Files Registration Statement For Proposed Follow-On Offering
2015-06-18,NeuroDerm Poster Selected For Blue Ribbon Highlights Session During 19th International Congress Of Parkinson's Disease And Movement Disorders Annual Meeting
2015-06-11,NeuroDerm Announces Start Of A Pharmacokinetic, Head-To-Head Comparison Study Of ND0612H And Duodopa(R)
2015-06-09,NeuroDerm's Latest Clinical Data Accepted As Late Breaking News To The International Parkinson And Movement Disorder Society's 19th International Congress On June 14-18, 2015 In San Diego
2015-06-02,NeuroDerm To Ring The Nasdaq Stock Market Opening Bell On June 3, 2015
2015-05-27,NeuroDerm Announces First Quarter 2015 Financial Results And Provides Corporate Update
2015-05-26,NeuroDerm CEO To Present At Jefferies 2015 Healthcare Conference On June 1, 2015
2015-05-20,NeuroDerm To Host First Quarter 2015 Financial Results Conference Call On May 27, 2015
2015-05-08,NeuroDerm Announces Lifting Of FDA Clinical Hold On ND0612, A Subcutaneously Delivered Levodopa/Carbidopa For The Treatment Of Parkinson's Disease
2015-04-29,NeuroDerm Files Annual Report On Form 20-F For The Year Ended December 31, 2014
2015-04-02,NeuroDerm Announces Fourth Quarter And 2014 Fiscal Year Financial Results And Provides A Corporate Update
2015-04-01,NeuroDerm To Announce Updated Topline Results Of Phase II Study Of Continuous, Subcutaneously-Delivered Levodopa/Carbidopa For The Treatment Of Parkinson's Disease At The 67th Annual Meeting Of The American Academy Of Neurology
2015-02-24,NeuroDerm CEO To Present At Upcoming Investor Conferences
2015-01-19,NeuroDerm Announces Extraordinary General Meeting Of Shareholders For Ratification Of Election Of External Directors And Adoption Of Compensation Policy
2014-12-31,Market News: Civeo Corp, Eagle Rock Energy Partners, Neuderm Ltd
2014-12-31,NeuroDerm (NDRM) Stock Plunges Today Following Tuesday's Gains
2014-12-30,Stocks Fall in Light Trading as Oil and Greece Weigh on Markets
2014-12-30,Market News: Neuroderm Ltd, Civeo Corp, Expedia Inc
2014-12-30,NeuroDerm (NDRM) Stock Skyrockets to One-Year High After Encouraging Parkinson's Treatment Results
2014-12-30,NeuroDerm Announces Topline Results Of Phase IIa Pharmacokinetic Study Of ND0612H And ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa For The Treatment Of Parkinson's Disease
2014-12-18,NeuroDerm Announces Third Quarter 2014 Financial Results And Provides A Corporate Update
2014-12-05,NeuroDerm CEO To Present At Oppenheimer Healthcare Conference On December 10, 2014
,
,
,
